Literature DB >> 11886336

Hürthle cell tumors: using molecular techniques to define a novel classification system.

Greg Belchetz1, Carol C Cheung, Jeremy Freeman, Irving B Rosen, Ian J Witterick, Sylvia L Asa.   

Abstract

BACKGROUND: Since ret/PTC gene rearrangements are specific to papillary thyroid carcinoma (PTC), the diagnosis of Hürthle cell PTC (HCPTC) has recently been expanded to include a subset of Hürthle cell tumors (HCTs) that may lack both papillary architecture and/or classic nuclear features but that harbor a ret/PTC gene rearrangement. We hypothesize that such HCPTCs behave in a fashion analogous to other papillary carcinomas, while Hürthle cell carcinomas (HCCs) behave similarly to follicular carcinomas. EDUCATIONAL
OBJECTIVES: At the conclusion of this article, participants should be able to discuss HCTs and to identify HCPTCS using molecular techniques.
METHODS: A retrospective chart review was carried out on 56 patients with HCTs. All pathological specimens were analyzed for ret/PTC gene rearrangements. Hürthle cell adenoma (HCA) was defined as an HCT that did not exhibit capsular and/or vascular invasion and that lacked a ret/PTC gene rearrangement when evaluated by immunohistochemical and reverse transcription polymerase chain reaction analysis. An HCC was defined as an HCT with capsular and/or vascular invasion that lacked a ret/PTC gene rearrangement, and an HCPTC was defined as any HCT that harbored a ret/PTC gene rearrangement.
RESULTS: The subclassification of the 56 HCTs was as follows: 21 HCAs, 15 HCCs, and 20 HCPTCs. No patients with HCA or HCC were ret/PTC positive. Five of the 6 patients with definite lymph node metastasis were in the HCPTC group, demonstrating that molecular analysis helps to explain biological behavior.
CONCLUSIONS: Hürthle cell neoplasms can now be classified using histopathological as well as molecular criteria. It appears that the new subclassification of malignant HCTs into follicular (HCC) and papillary (HCPTC) variants identifies 2 distinct biological groups.

Entities:  

Mesh:

Year:  2002        PMID: 11886336     DOI: 10.1001/archotol.128.3.237

Source DB:  PubMed          Journal:  Arch Otolaryngol Head Neck Surg        ISSN: 0886-4470


  8 in total

1.  PVALB, a new Hürthle adenoma diagnostic marker identified through gene expression.

Authors:  Janete M Cerutti; Gisele Oler; Rosana Delcelo; Rene Gerardt; Pedro Michaluart; Sandro J de Souza; Pedro A F Galante; Peng Huang; Gregory J Riggins
Journal:  J Clin Endocrinol Metab       Date:  2010-10-06       Impact factor: 5.958

Review 2.  The role of immunohistochemical markers in the diagnosis of follicular-patterned lesions of the thyroid.

Authors:  Sylvia L Asa
Journal:  Endocr Pathol       Date:  2005       Impact factor: 3.943

Review 3.  Hurthle Cell Lesion: Controversies, Challenges, and Debates.

Authors:  Michael Shawky; Mahmoud Sakr
Journal:  Indian J Surg       Date:  2015-10-30       Impact factor: 0.656

4.  Type and prevalence of BRAF mutations are closely associated with papillary thyroid carcinoma histotype and patients' age but not with tumour aggressiveness.

Authors:  Vítor Trovisco; Paula Soares; Ana Preto; Inês Vieira de Castro; Jorge Lima; Patrícia Castro; Valdemar Máximo; Tiago Botelho; Severina Moreira; Ana Margarida Meireles; João Magalhães; Alexander Abrosimov; José Cameselle-Teijeiro; Manuel Sobrinho-Simões
Journal:  Virchows Arch       Date:  2005-05-19       Impact factor: 4.064

5.  Molecular detection of PPAR gamma rearrangements and thyroid carcinoma in preoperative fine-needle aspiration biopsies.

Authors:  Christopher A French; Jonathan A Fletcher; Edmund S Cibas; Christopher Caulfield; Paulette Allard; Todd G Kroll
Journal:  Endocr Pathol       Date:  2008       Impact factor: 3.943

Review 6.  My approach to oncocytic tumours of the thyroid.

Authors:  S L Asa
Journal:  J Clin Pathol       Date:  2004-03       Impact factor: 3.411

7.  Genetic and biological subgroups of low-stage follicular thyroid cancer.

Authors:  Christopher A French; Erik K Alexander; Edmund S Cibas; Vania Nose; Julia Laguette; William Faquin; Jeff Garber; Francis Moore; Jonathan A Fletcher; P Reed Larsen; Todd G Kroll
Journal:  Am J Pathol       Date:  2003-04       Impact factor: 4.307

Review 8.  Oncocytic Change in Thyroid Pathology.

Authors:  Sylvia L Asa; Ozgur Mete
Journal:  Front Endocrinol (Lausanne)       Date:  2021-05-03       Impact factor: 5.555

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.